Introduction
Attention deficit hyperactivity disorder (ADHD) is known to be a condition that affects the behavior of people. The condition is characterized by features like impulsivity, hyperactivity, lack of sleep, anxiety disorders, and inattention that affect normal functionality in human life. Mostly, ADHD attacks children at a young age; however, in some instances, people are diagnosed with the condition at an adult age.
Medical practitioners use prescription stimulants such as Adderall or Ritalin as medical interventions to mitigate the risks related to ADHD disorder by decreasing disruptive behaviors and increasing an individual’s focus. Research shows that ADHD vulnerability is higher in the United States (US) compared to the United Kingdom (UK). For example, in the US, out of 1000 children aged between 4 and 13 years, 69 of them are taking ADHD medication, while in the UK, out of 1000 kids aged between 5 and 13 years, 9 of them are being diagnosed with ADHD (Abdelnour, Jansen, and Gold, 2022, p. 467). The comparison of ADHD diagnosis and drug use in children and adolescents between the US and the UK shows a significant disparity between the two countries.
Many major factors surely lead to this difference in the diagnosis and management of ADHD. The first difference is in the structure of healthcare systems. In the US, universal public health insurance is unavailable because diagnoses and treatment depend on private insurance. As a result, this may cause differences in diagnosis and care.
Contrastingly, the UK’s National Health Service ensures equal access for all children. Besides, direct pharmaceutical promotion to consumers is allowed in the US but banned in the UK, undoubtedly resulting in greater public awareness and demand. ADHD diagnostic criteria in the US are less objective and broader than what prevails in the UK, where standards are more restrictive. In addition, financial incentives in the private US healthcare system stimulate overdiagnosis and profit-driven medication prescribing.
Such systemic differences in the US and UK healthcare, as well as ADHD systems, seem to contribute significantly to different approaches for dealing with. However, the exact reasons for the divergence remain unclear. It is necessary to develop intensive intercultural studies, which will find the reasons and consequences of the various rates.
For instance, in-depth studies that would compare diagnostic pathways, medication prescription practices, school-based interventions, and cultural perceptions could provide insights into why ADHD identification is much greater in the US. Randomized controlled studies globally in various populations are important to determine guidelines that will universally work for diagnosing ADHD, balanced with effective treatment being given depending on the child. In all, the significant difference in ADHD diagnosis between these two countries highlights not just how essential more rigorous cross-national research is to understand such disparities but also what types of optimal evidence-based standards can cope with varying contexts.
The essay intends to address the medical implications of using ADHD drugs and links to the UK’s special education needs policies while looking at the medical and social disability model. This will be compared and contrasted with other studies worldwide, especially in the US, where the diagnosis rate is higher because the healthcare system is not centralized and care is driven by financial motives.
Prevalence of ADHD Diagnosis
ADHD Rates in the United States
Various studies have demonstrated that the identification of ADHD has risen over the past two to three decades. For instance, a nationally representative study on diagnosis prevalence reported that in 1998, approximately 6.1 percent of American youth were diagnosed with ADHD by health professionals. By the year 2007, this percentage increased to a whopping 9% of children (Danielson et al., pp.1685-1697). By 2019, the rate of diagnosis reached more than 9.5%, showing that over 10 percent of children in the US were being diagnosed with ADHD.
Statistics from the CDC provide evidence that this rate of identification increased gradually over the following years, coming to 9.4% by 2016 (Danielson et al., pp.1685-1697). In total, ADHD diagnosis among American children is estimated to have gone up more than fifty percent between 1998 and 2019 (Danielson et al., pp.1685-1697). This continuous rise has seen ADHD become one of the most frequently diagnosed mental health conditions affecting children across America. Finally, regional analysis reveals that ADHD identification rates have steadily increased in all regions of the United States.
ADHD Rates in the United Kingdom
Although ADHD diagnosis rates in the UK are below those of the US, they have risen significantly over the past few years. According to research, the incidence of childhood and adolescent ADHD rose threefold in Britain from the late 1980s through early 2000 (Eke et al., 2020, pp.616-622). The prevalence increased over the years from an estimated 2-5% of diagnosed youths in the 1980s to 6-8% by the end of their twenties (Di Lorenzo et al., 2021, pp. 283-298). Figures are only estimates because studies differ on this matter. This steady increase in the identification of ADHD among young British people has led to some worries regarding possible overdiagnosis. The comparison experts make is that the rates of increase are not astronomical, as in the US. A more moderate incline implies that UK clinicians may be adopting a relatively conservative diagnostic approach for ADHD relative to their American counterparts. However, the rise of ADHD diagnosis in UK youth remains unexplained.
Factors Contributing to Differing Rates
The significant difference in ADHD diagnosis rates between the U. S and the UK is probably due to several key factors. The latter includes the structure of the health care systems, which are significantly different. The US does not have a universal public health insurance system, and widespread access is dependent on private insurance coverage(Galvani et al., 2020, pp.524-533). ADHD diagnosis and medication treatment for poor and minority children are less likely. The UK’s National Health Service offers equal healthcare access for all children regardless of their socioeconomic status.
Furthermore, direct-to-consumer pharmaceutical advertising of ADHD medications is allowed in the US but outlawed in the UK, and likely influences public consciousness and demand. The rates of diagnosis and treatment, in turn, are most likely driven by aggressive marketing campaigns on the part of American drug companies targeting parents and children (Yalcin, 2020, p. 1). In addition, the main diagnostic criteria and recommendations vary for both countries.
To compare, the DSM criteria used in the US could be more subjective and broader than those of ICD-10 adopted in the UK (Peasgood et al., 2021, pp. 1962-1976). Disorder prevalence depends on diagnostic thresholds and their application. The privatized US system incorporates financial rewards that promote excessive use of the ADHD label and prescription drugs (Baweja, Soutullo, and Waxmonsky, 2021, p.1206). For the sake of profit motives, overdiagnosis is not observed in the NHS.
Concerns About Potential Overdiagnosis in the US
The fact that the diagnosis and medication use for ADHD in children and adolescents is significantly higher than in countries such as the UK has also raised concern among some researchers about overdiagnosis. However, critics maintain that normal childhood behaviors are frequently referred to as ADHD or other disorders based on questionable diagnostic thresholds (Taylor, Kaplan-Kahn, Lighthall, and Antshel, 2021, pp. 1-19). They argue that the definitions of ADHD as a disability are too inclusive, causing over‐diagnosis and high medication use with possible side effects for children. In the same way, the diagnosis of ADHD in children can have another tendency to stigmatization and self-fulfillment.
On the other hand, others claim that it might just be a sign of higher ADHD rates in the USA compared with much lower reported rates within countries like those in the UK. They contend that further screening should be carried out in various other healthcare settings to determine if ADHD is being correctly diagnosed and treated. International research comparing ADHD assessment methods to determine whether differing rates reflect overdiagnosis in one setting and underdiagnosis in others could facilitate this (Gascon, Gamache, St‐Laurent, and Stipanicic, 2022, pp. 2363-2380). Even today, whether this implies inaccurate labeling and overmedication of American children or other nations’ need to enhance diagnosis and treatment is yet an open question. Resolving this debate requires the continued research of cross-national variations in ADHD classification and intervention.
Medications Used to Treat ADHD
Stimulants
The most common forms of pharmacological treatment for ADHD include stimulant drugs such as methylphenidate (Ritalin) and amphetamine-dextroamphetamine (Adderall). They have been used for ADHD care for many years and are often the first line of medication prescribed. By increasing the amount of dopamine and norepinephrine in the brain, stimulants activate the central nervous system (Docherty and Alsufyani, 2021, pp. S53-S69). This aims at improving focus and concentration in about 70% of patients(Docherty and Alsufyani, 2021, pp. S53-S69).
Apart from stimulant medications, several newer non-stimulants have also been sanctioned for treating ADHD. These include drugs such as atomoxetine (Strattera), clonidine, and guanfacine. If stimulant drugs have proved ineffective or have had intolerable side effects, non-stimulants are generally utilized.
Non-Stimulants
Non-stimulants operate differently from stimulants, such as Ritalin or Adderall, which act via a different mechanism of action. For instance, atomoxetine is a selective norepinephrine reuptake inhibitor; thus, the enhancement of signaling of the neurotransmitter in brain sections occurs due to its physical blocking, which prevents absorption (Idrees et al., 2023, p. 104968). Studies show that when it comes to non-stimulants, most individuals are slightly less effective than stimulant interventions in the treatment of core ADHD symptoms. The latter includes inattention, hyperactivity, and impulsivity (Eaton et al., 2022). Nevertheless, they are an alternative for individuals who poorly react to or cannot handle stimulant adverse effects.
There remains a need for more long-term comparative studies performed between stimulant and non-stimulant medications. Their relative impacts on variables such as academic and occupational performance, quality of life, and risk for substance abuse dependence should be evaluated in future research studies (Kazda et al., 2022). This could assist in the development of more precise instructions concerning the best medication options for the personalized treatment of ADHD. Specifically, the creation of more personalized medication regimens continues to be an important objective in enhancing long-term prognoses in ADHD.
ADHD Medication Implications
The most common side effects of ADHD stimulant medicines are loss of appetite, headache, gastrointestinal upset such as nausea and abdominal pain, insomnia, or irritability. As a result, this leads to hindrance of the young people by affecting their well-being, quality of life, and adherence to treatment schemes (Morgan, Woods, and Wang, 2023, pp.359-370). However, stimulants can cause growth delay, which is a potential adverse effect that may affect ADHD children with ADHD prescribed these drugs throughout childhood (Carucci et al.,2021, pp.509-525).
Height and weight monitoring are needed to screen for slow growth that may indicate a need for drug breaks. In an even more serious sense, cardiovascular side effects of ADHD medications may also include accelerated heart rate and blood pressure that need to be watched over for those at risk (Behlke, Lenze, and Carney, 2020, pp.1133-1147). In addition, stimulants such as methylphenidate and amphetamines have intrinsic addictive properties associated with their reward effect in the brain (Tomasi et al., 2023). However, improper use is of great concern, especially among adolescents and college students.
The most alarming aspect is that the long-run neurological effects of ADHD medication use on brain development appear unknown, particularly for children who are prescribed stimulants such as Ritalin and Adderall for many years through much of their critical period from childhood to adolescence (Farhat et al., 2022, pp.1562-1572). While many substantial short-term advantages have been established, little rigorous investigation has looked at the effects of long-term chronic stimulant use over the years on the developing brain.
Several recent studies conclude that the positive effects decrease with longstanding treatment and academic performance, and behavior diminishes within the first few years of treatment (Borgen, Frønes, and Raaum, 2021, pp.2089-2105). Longitudinal research is critically needed to improve our understanding of the long-term efficacy and cost against safety concerns like possible neurological development impacts (Long and Fink, 2021, p.2858). In the absence of evidence regarding long-term outcomes, experts broadly agree to carefully monitor and cautiously prescribe stimulant medications for ADHD, especially in children.
The UK’s legal framework and policies pursue a global approach that concentrates on addressing individual needs by eliminating hurdles that can prevent students with ADHD from learning. The graduated threshold provides selective SEN provision at the outset of mainstream schooling. For more complex additional support than this, EHC plans are formulated detailing education, health, and social care provision designed specifically for the child with periodic reviews (Sirari et al., 2023). In contrast with the medical approach accentuated in the US, the UK embraces a social model of disability that gives preference to behavioral treatments and family and classroom interventions rather than medication.
UK Educational Policies and Programs for ADHD Students
In the UK, individuals with special educational needs and disabilities SEND), including those diagnosed as ADHD, are covered under the current Children and Families Act 2014 and SEND Code of Practice. This was legislation and guidance that superseded previous laws, such as the Special Educational Needs and Disability Act 2001, with reforms introduced in 2014 (Borkett, 2020, pp.1-184). This was aimed at enhancing SEND services, assessments, and support. Individual education plans were replaced by EHC under the new framework for children with complex special educational needs needing substantial support. The SEND Code of Practice is the statutory guidance for identifying and assessing eligibility for services supporting students with conditions such as ADHD through a uniform, equitable national approach.
The graduated threshold model in the UK has two tiers of support, namely SEN Support and EHC plans. Similarly, SEN Support provides additional support for special students whose disabilities are more pronounced and elaborate that they cannot be adequately handled with SEN support only(Szumski, Smogorzewska, and Grygiel, 2022). The plans are detailed, legally enforceable documents drawn up by local authorities that set out the types of educational, health, and social services required for each child, with mandatory periodic review. Unlike the individualized education programs (IEPs) applied in the US, EHC plans required by the UK focus more on a whole-child approach that not only incorporates educational needs but also health and social requirements of supporting this child.
Interestingly, the UK model of special needs support is based on a social viewpoint regarding disability. This approach views society’s barriers and inadequate accommodations as disabling rather than the medical state directly making someone disabled. There is more attention given to eliminating obstacles and enablers in which the students realize their full potential, not medical correction or normalization of this state (Edwards, Poed, Al-Nawab, and Penna, 2022, pp.779-799). As such, with this approach in mind, the use of ADHD medications is carefully monitored and not a standard first-line treatment method. Behavioral, educational, and family interventions are given priority.
Conclusion
In summary, American and British children differ significantly in the rates of ADHD diagnosis and medication use. The increased prevalence in the US relative to the UK can be related to differences between their healthcare systems, educational policies, differential diagnostic criteria, and cultural attitudes towards them. Such a difference shows how the diagnosis and management of ADHD in youth can be influenced by a nation’s approach towards behavioral disorders, as well as learning disabilities. This divergence requires further cross-cultural research to identify the underlying causes of such deviation and develop effective diagnostic and treatment guidelines that are fit for the different cultures. Comprehensively, the figures for ADHD diagnosis among American children have consistently increased in recent years and have prompted suspicion of its possible overdiagnosis.
Critiques point out that ambiguous diagnostic thresholds result in misdiagnosis of otherwise normal childhood behaviors as ADHD, which leads to excessive medication administration with possible side effects. Contrastingly, it is argued that high rates in the US may point to a genuine increase in ADHD cases requiring intensified screening and treatment. Addressing this controversy would need more research, looking at comparative international studies to determine whether disparate frequencies indicate over-testing in one country and underdiagnosis elsewhere. No matter how individualized medication prescriptions are based on every child’s response, tolerance must still be achieved.
The main pharmacological treatment options for ADHD include stimulant medications such as Ritalin and Adderall, which increase dopamine and norepinephrine transmission in the brain, and alternatives to stimulants, like Strattera, which is somewhat less effective but better tolerated. The beneficial effects of the drugs are short-lived in that their long-term impact on brain development is, however, unknown because a child may take them for years. Thus, professionals advise a cautious tracking of side effects and growth in prescribing stimulants to children. The long-term efficacy and safety of medications need to be further researched.
Although pharmacological and educational interventions are essential in treating ADHD, relying too much on either one or the other is most likely counterproductive. A developmentally appropriate strategy consists of an intelligent mix based on medication as necessary and behavioral therapy with academic support, adjusted to the child’s continuing needs. However, more cross-national research is essential to identify best practices that offer a balance of efficacy, safety, and quality of life for children in considering the sociocultural context. In general, when talking about ADHD, it should focus on how to allow people to fulfill their potential by highlighting a patient-centered, multi-dimensional, and developmentally appropriate model of care.
Reference List
Abdelnour, E., Jansen, M.O. and Gold, J.A. (2022) ‘ADHD diagnostic trends: increased recognition or overdiagnosis?‘ Missouri Medicine, 119(5), p.467.
Baweja, R., Soutullo, C.A. and Waxmonsky, J.G. (2021) ‘Review of barriers and interventions to promote treatment engagement for pediatric attention deficit hyperactivity disorder care‘, World Journal of Psychiatry, 11(12), p.1206.
Behlke, L.M., Lenze, E.J. and Carney, R.M. (2020) ‘The cardiovascular effects of newer antidepressants in older adults and those with or at high risk for cardiovascular diseases‘, CNS drugs, 34, pp.1133-1147.
Borgen, N.T., Frønes, I. and Raaum, O. (2021) ‘Impact of the school environment on medical treatment of attention deficit hyperactivity disorder: a population‐wide register data study of school‐wide positive behavioral interventions and supports’, Child Development, 92(5), pp.2089-2105.
Borkett, P. (2020) ‘Special educational needs in the early years: a guide to inclusive practice’, Special Educational Needs in the Early Years, pp.1-184.
Carucci, S. et al. (2021) ‘Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis’, Neuroscience & Biobehavioral Reviews, 120, pp.509-525.
Danielson, M.L. et al. (2022) ‘State-level estimates of the prevalence of parent-reported ADHD diagnosis and treatment among US children and adolescents 2016 to 2019‘, Journal of Attention Disorders, 26(13), pp.1685-1697.
Di Lorenzo, R. et al. (2021) ‘Children and adolescents with ADHD followed up to adulthood: a systematic review of long-term outcomes’, Acta Neuropsychiatrica, 33(6), pp.283-298.
Docherty, J.R. and Alsufyani, H.A. (2021) ‘Pharmacology of drugs used as stimulants,’ The Journal of Clinical Pharmacology, 61, pp.S53-S69.
Eaton, C. et al. (2022) ‘Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy‘, Cochrane Database of Systematic Reviews, (7).
Edwards, M., Poed, S., Al-Nawab, H. and Penna, O. (2022) ‘Academic accommodations for university students living with disability and the potential of universal design to address their needs‘, Higher education, 84(4), pp.779-799.
Eke, H. et al. (2020) ‘Transition between child and adult services for young people with attention-deficit hyperactivity disorder (ADHD): findings from a British national surveillance study’, The British Journal of Psychiatry, 217(5), pp.616-622.
Farhat, L.C. et al. (2022) ‘The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis‘, Molecular Psychiatry, 27(3), pp.1562-1572.
Galvani, A.P. et al. (2020) ‘Improving the prognosis of health care in the USA‘, The Lancet, 395(10223), pp.524-533.
Gascon, A., Gamache, D., St‐Laurent, D. and Stipanicic, A.(2022) ‘Do we over‐diagnose ADHD in North America? A critical review and clinical recommendations,’ Journal of Clinical Psychology, 78(12), pp.2363-2380.
Idrees, I., Bellato, A., Cortese, S. and Groom, M.J. (2023) ‘The effects of stimulant and non-stimulant medications on the autonomic nervous system (ANS) functioning in people with ADHD: a systematic review and meta-analysis’, Neuroscience & Biobehavioral Reviews, 144.
Kazda, L. et al. (2022) ‘Association of attention-deficit/hyperactivity disorder diagnosis with adolescent quality of life‘, JAMA Network Open, 5(10).
Long, D.A. and Fink, E.L. (2021) ‘Transitions from short to long-term outcomes in pediatric critical care: considerations for clinical practice’, Translational Pediatrics, 10(10), p.2858.
Morgan, P.L., Woods, A.D. and Wang, Y. (2023) ‘Sociodemographic disparities in attention-deficit/hyperactivity disorder overdiagnosis and overtreatment during elementary school‘, Journal of Learning Disabilities, 56(5), pp.359-370.
Peasgood, T. et al. (2021) ‘What is the health and well-being burden for parents living with a child with ADHD in the United Kingdom?‘, Journal of Attention Disorders, 25(14), pp.1962-1976.
Sirari, T. (2023) ‘Development and economic evaluation of a patient-centered care model for children with Duchenne muscular dystrophy: protocol for a quasi-experimental study’, JMIR Research Protocols, 12(1), p.e42491.
Szumski, G., Smogorzewska, J. and Grygiel, P. (2022) ‘Academic achievement of students without special educational needs and disabilities in inclusive education–Does the type of inclusion matter?‘ Plos one, 17(7).
Tomasi, D. et al (2023) ‘Examining the role of dopamine in methylphenidate’s effects on resting brain function‘, Proceedings of the National Academy of Sciences, 120(52).
Taylor, L.E., Kaplan-Kahn, E.A., Lighthall, R.A. and Antshel, K.M. (2021) ‘Adult-onset ADHD: a critical analysis and alternative explanations‘, Child Psychiatry & Human Development, pp.1-19.
Yalcin, E.H. (2020) ‘The Pharma Perspective: the double-edged sword of direct-to-consumer advertising‘, Health Law Outlook, 11(1), p.1.